These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 29523126)

  • 1. MYC amplification in subtypes of breast cancers in African American women.
    Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
    BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
    Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
    J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
    Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
    Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
    Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
    Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
    JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Histopathological Markers with Clinico- Pathological Factors in Mexican Women with Breast Cancer.
    Bandala C; De la Garza-Montano P; Cortes-Algara A; Cruz-Lopez J; Dominguez-Rubio R; Gonzalez-Lopez JN; Cardenas-Rodriguez N; Alfaro-Rodriguez A; Salcedo M; Floriano-Sanchez E; Lara-Padilla E
    Asian Pac J Cancer Prev; 2015; 16(18):8397-403. PubMed ID: 26745092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
    Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women; hospitals based case series.
    Sengal AT; Haj-Mukhtar NS; Elhaj AM; Bedri S; Kantelhardt EJ; Mohamedani AA
    BMC Cancer; 2017 Dec; 17(1):804. PubMed ID: 29191181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer molecular subtypes and receptor status among women at Potchefstroom Hospital: a cross-sectional study.
    Kakudji BK; Mwila PK; Burger JR; du Plessis JM; Naidu K
    Pan Afr Med J; 2021; 38():85. PubMed ID: 33889251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
    BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.
    Xu R; Feiner H; Li P; Yee H; Inghirami G; Delgado Y; Perle MA
    Arch Pathol Lab Med; 2003 Nov; 127(11):1458-64. PubMed ID: 14567723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
    Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
    Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hormone receptor status in breast cancer and the relationship of subtypes with clinicopathological features.
    Senel F
    Indian J Pathol Microbiol; 2021; 64(4):671-676. PubMed ID: 34673584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.
    John EM; Koo J; Phipps AI; Longacre TA; Kurian AW; Ingles SA; Wu AH; Hines LM
    Breast Cancer Res; 2024 May; 26(1):88. PubMed ID: 38822357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.